3,5-diisopropylsalicylic acid (DIPS)

1.	Young, S: 1 article (01/2005)
2.	Foret, C J: 1 article (01/2005)
3.	Corbellini, C: 1 article (01/2005)
4.	Janowicz, P: 1 article (01/2005)
5.	Heilmann, V: 1 article (04/2001)
6.	Melsheimer, P: 1 article (04/2001)
7.	von Knebel Doeberitz, M: 1 article (04/2001)
8.	Dürst, M: 1 article (04/2001)
9.	Nees, M: 1 article (04/2001)
10.	Klaes, R: 1 article (04/2001)

Related Diseases

1.	Mastitis 08/01/1998 - "Three postmilking teat dips were tested for efficacy against Staphylococcus aureus and Streptococcus agalactiae in two separate studies using experimental challenge procedures that were recommended by the National Mastitis Council. " 11/01/1997 - "The model for the experimental challenge in the trials that were designed to test the efficacy of the two postmilking teat dips was recommended by the National Mastitis Council. " 12/01/2000 - "We tested two postmilking teat dips for efficacy against Staphylococcus aureus and Streptococcus agalactiae using experimental challenge procedures recommended by the National Mastitis Council. " 10/01/1994 - "Two postmilking teat dips were tested for efficacy against Staphylococcus aureus and Streptococcus agalactiae using experimental challenge procedures recommended by the National Mastitis Council. " 01/01/2002 - "Application of the two new postmilking teat dips was effective in reducing new IMI from contagious mastitis pathogens. " Order ALL the reference details at left...
2.	Infection 02/01/1975 - "Four teat dips were highly effective in reducing the incidence of udder infection. " 07/01/2006 - "Both dips were significantly effective in reducing new contagious intramammary infections. " 01/01/1998 - "Five Michigan dairy herds participated in a split-herd study to compare the efficacy of two postmilking teat dips in the prevention of new intramammary infections (IMI) in lactating cows. " 11/01/1980 - "The efficacy of teat dips of differing persistence on teat skin in preventing intramammary infection by Streptococcus uberis and Escherichia coli in dry cows." 12/07/2009 - "Results indicate correspondence between dips in transmission and school holidays for some infections, but there are puzzling discrepancies, despite close correspondence between average age of infection and age of schooling. " Order ALL the reference details at left...
3.	Asthma (Bronchial Asthma) 01/01/1997 - "We conclude that a subset of clinically stable asthma patients presents morning dips and nocturnal waking. " 04/01/1990 - "Four of these 14 patients were readmitted with acute severe asthma during the 8 weeks follow-up period; in contrast, none of the 16 patients without major dips required readmission. " 07/07/1984 - "Inhaled therapy for morning "dips" in asthma." 05/26/1984 - "Inhaled therapy reduces morning dips in asthma." 10/01/1981 - "Furthermore in patients with unstable bronchial asthma and in patients with morning dips in PEF the more stable plasma concentration may perhaps keep the patients in a more steady state." Order ALL the reference details at left...
4.	Seizures (Seizure) 01/01/1999 - "A decrease in NO synthesis in animal models of seizure and radiation injury may account for the anticonvulsant, radioprotectant, and radiorecovery activities of Mn(3)(3,5-DIPS)(6) and Cu(II)(2)(3,5-DIPS)(4)." 03/01/2002 - "It was pointed out that the Cu(2)(DIPS)(4)L(2) complexes (L=diethylether, N,N-dimethylformamide) exhibited no rotorod toxicity when examined for anticonvulsant activity using the seizure produced by maximal electroshock, following oral administration to rats." 11/01/2004 - "While the two ternary phenanthroline-containing complexes, 1 and 2, evidenced weak protection against maximal electroshock (MES)- and subcutaneous Metrazol (scMET) induced seizures, [Zn(II)(3,5-DIPS)(2)(DMSO)(2)], [Zn(II)(aspirinate)(2)(H(2)O)(2)], and bis(salicylato)-1,10-phenanthorlinezinc(II), [Zn(II)(salicylate)(2)(phen)], were found to be particularly useful in protecting against MES and scMET seizures and [Zn(II)(aspirinate)(2)(H(2)O)(2)] and [Zn(II)(salicylate)(2)(phen)] were found to have activity in protecting against Psychomotor seizures, without causing Rotorod toxicity. " 07/15/2000 - "Two binuclear copper(II) complexes of 3,5-diisopropylsalicylic acid were characterized by single crystal X-ray diffraction methods and examined for anti-inflammatory activity using activated polymorphonuclear leukocytes and for anticonvulsant activities using electroshock and metrazol models of seizures. " 01/01/1991 - "1. The effects of the octapeptide angiotensin II (AT II) on some types of behaviour [threshold of seizures induced by timed intravenous infusion of pentylenetetrazol (PTZ), exploratory behaviour: ambulation, rearing and head-dips on a hole-board, and passive avoidance performance--step-through paradigm] were studied following repeated systemic administration of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to mice (30 mg/kg, i.p., twice daily for 5 days). " Order ALL the reference details at left...
5.	Apnea 01/01/2007 - "An increase in apnea-hypopnea index (18.9 vs. 4.3; p = 0.007) and dips in the SaO(2) (> or =4%) per hour of sleep (22.6 vs. 6.4; p = 0.021) were also significantly greater in hemodialysis patients than controls. " 01/01/2007 - "CONCLUSIONS: The patients on hemodialysis showed poor sleep quality with a significant increase in the apnea-hypopnea index and in the number of dips in SaO(2). " 04/01/2005 - "Sleep-disordered breathing was assessed by the apnea-hypopnea index, the SaO(2) nadir, and the desaturation index, including dips in saturation below 90% (DI(90)). " 07/01/2007 - "MEASUREMENTS AND RESULTS: Breathing flow, pressure, CO2 air concentration, and SpO2 showed that the model mimicked OSA respiratory events (obstructive apneas, increased respiratory efforts, and oxygen saturation dips). " 01/01/2008 - "Main sleep quality and respiratory variables were recorded: number of dips in oxygen saturation (SaO(2)) > or =3% per hour of sleep; percentage of sleep time with SaO(2) <90%; percentage of sleep time in apnea and hypopnea, and sleep apnea/hypopnea index (AHI). " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Iodine
2.	Pentylenetetrazole (Metrazol)
3.	Progesterone
4.	Prednisolone (Predate)
5.	Dimethyl Sulfoxide (DMSO)
6.	Bronchodilator Agents (Bronchodilators)
7.	amitraz (Taktic)
8.	triphosphoric acid (triphosphate)
9.	diazenedicarboxylic acid bis(N'-methylpiperazide)
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Ligation
3.	Antibiotic Prophylaxis
4.	Intensive Care (Surgical Intensive Care)
5.	Stents

Best Treatments:
Research Summary Report
on Mastitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 129 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>